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LETTERS TO THE EDITORRegarding “A new approach to carotid angioplasty
and stenting with transcervial occlusion and
protective shunting: Why it may be a better carotid
artery intervention”
Our method for achieving flow reversal to prevent emboli
during CAS via a cervical approach (J Vasc Surg 2004;39:994-
1002) is similar to one described by Parodi et al1 to achieve the
same ends via a transfemoral approach. We had acknowledged this
in an early draft of our article. Although the Parodi device is cited
in the references of the published version, direct reference in the
body of the text was omitted because of limitations on space.
David Chang, MD
Stanford University School of Medicine
San Jose, Calif
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Regarding “Aortofemoral bypass in young patients
with premature atherosclerosis: Is superficial femoral
vein superior to Dacron?”
Morasch et al used the term “superficial femoral vein” in their
article, “Aortofemoral bypass in young patients with premature
atherosclerosis: Is superficial femoral vein superior to Dacron?” (J
Vasc Surg 2004;40:17-23). This terminology should not be used
in a medical publication.
Caggiati et al1 argued that the unauthorized term “superficial
femoral vein” should not be used for the femoral vein, which is,
without doubt, a deep vein. Also, “superficial femoral vein” is not
in the Terminologica Anatomica.
This same mistake was made by Modrall et al,2 who used the
term in their article, “Comparison of superficial femoral vein and
saphenous vein as conduits for mesenteric arterial bypass.”
A common anatomic terminology is the foundation for a
common language in phlebologic sciences. Further, such a com-
mon language is important for investigation of the vascular system
and for accurate diagnosis and correct treatment.
It is unfortunate that the above misusage was overlooked by
the editor and reviewer of such a fine journal as Journal of Vascular
Surgery. We hope that in the future more effort will be made for
better reference.
Geun Eun Kim, MD, Professor
Bae Joo Yul, Medical student
Department of Vascular Surgery, Asan Medical Center
University of Ulsan, College of Medicine
Seoul, Korea
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Reply
The editors thankDrs Kim and Yul for pointing out the proper
terminology that should have been used in the 2 papers published
in the Journal concerning use of femoral and popliteal vein seg-
ments for arterial reconstructive procedures. Both of these papers
are from the vascular surgery group at the University of Texas
Southwestern, who pioneered these techniques at a time when the
femoral vein was still commonly termed the “superficial femoral
vein.” Subsequent usage of this incorrect term has persisted, and
indeed was not corrected by the editors during the review process
for these 2 recent papers. We completely agree with Drs Kim and
Yul that a common language is important for accurately commu-
nicating new scientific information.
J. L. Cronenwett, MD
Lebanon, NH
J. Seeger, MD
Gainesville, Fla
doi:10.1016/j.jvs.2004.09.002
Regarding “Floating thoracic aortic thrombus in
‘protein S’ deficient patient”
We read with interest the report by Hazirolam et al (J Vasc
Surg 2004;40:381) describing a floating thoracic aortic thrombus
in a woman with protein C deficiency. The authors report that she
was treated with warfarin, but no mention is made of whether a
prior treatment with heparin was carried out. It is known that
protein C and, in particular, protein S deficiency may be predispos-
ing conditions for occurrence of acute arterial thrombosis.1 War-
farin decreases the production not only of vitamin K–dependent
clotting factors, but also of protein C, an endogenous anticoagu-
lant factor. Protein S acts as a cofactor permitting the inhibitory
function of protein C, which is fully dependent on protein S to
express its anticoagulant activity.2 At the beginning of warfarin
therapy, protein C and factor VII rapidly drop, whereas factor X
and prothrombin levels decrease in 3 to 9 days. The difference in
kynetics—eg, factor VII and protein C have a short half-life (about
6-8 hours), prothrombin has a longer one (approximately 100
hours), and factors IX and X have an intermediate half-life—may
lead to a transitory hypercoagulative status, particularly during the
first 12 to 26 hours of warfarin administration.3 We have described
a fatal case of acute thorombosis of abdominal aorta in a female
patient shortly after starting warfarin therapy without previously
being treated with heparin for the onset of atrial fibrillation.4 The
observation that protein C and protein S deficiency may predispose
to warfarin-induced skin necrosis and thrombosis, however, does
not mandate that their levels always be measured before starting
oral anticoagulant therapy. The rarity of this and other genetic
trombophilic associations5 and their possible complications, in
fact, makes this approach impractical. However, to prevent possi-
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therapeutic dose of heparin during the critical initial window, then
start with low doses of warfarin, and gradually increase the dose
until the therapeutic range is reached.
Roberto Manfredini, MD
Benedetta Boari, MD
Massimo Gallerani, MD
Section of Internal Medicine, Gerontology and Geriatrics
Department of Clinical and Experimental Medicine
University of Ferrara
Ferrara, Italy
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Reply
We thankDrManfredini and his colleagues for their interest in
this topic and agree with their assessment. The patient we have
described initially presented 2 years previously to another hospital
with deep venous thrombosis and at that time she underwent
anticoagulation therapy with heparin as an inpatient, followed by
transition to warfarin therapy. Her records indicate that the aortic
thrombus (as well as thrombus involving upper extremities) oc-
curred despite concurrent warfarin therapy.
Bruce A. Perler, MD
David A. Bluemke, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, Md
doi:10.1016/j.jvs.2004.08.018
Regarding “Decreased use of iliac extensions and
reduced graft junctions with software assisted
centerline measurements”
The study by Valazquez et al (J Vasc Surg 2004;40:222-7)
demonstrates that computer-derived centerline measurements al-
low sufficiently precise estimates of endograft fabric length, and
thus endograft sizing can be planned more accurately before
surgery. This results in a lesser requirement for iliac extensions and
endograft junctions in genera,l as compared with the era when the
authors used sizing catheter and calipers for estimating endograft
length.
This was first described by our laboratory in March 20001 in a
study that demonstrated the superior accuracy of our computer-
generated central flowline (centerline) measurements of length
over sizing catheter and caliper measurements. The computer
software program was validated with glass phantoms, with mea-surements simultaneously carried out with electronic calipers for
length and pyknometry for volume. Since then we have noted that
endografts vary considerable in flexibility and stiffness. For exam-
ple, the Guidant unsupported endograft and our own homemade
polytetrafluoroethylene endograft1 are at the flexible end of the
spectrum, and the less flexible AneuRx endograft is at the stiffer
end. The sizing catheter takes the shortest route (“as the crow
flies”) through the various angulations of the aneurysm from the
proximal to the distal landing site. To confuse matters further, the
stiffness of the sizing catheter is quite different from that of the stiff
endografts. Fabric length calculated by this means is shorter than if
one used the central flow line.
Because of this, using central flowline measurements we select
a slightly longer fabric length when using a flexible endograft than
with a stiffer device. Even so, there is an element of guesswork in
selection of the final fabric length. We concur with Velazquez et al
that computer-generated central flowline measurements are more
accurate and represent a better guide for endograft sizing and
planning.
M. Adiseshiah, FRCS
Consultant Vascular/Endovascular Surgeon
University College London Hospitals
London, England
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We appreciate and thank Dr Adiseshiah for comments offered
in agreement with our recently reported findings.1 We are familiar
with the noted previous study in which phantom glass aneurysms
filled with contrast material were used to validate the accuracy and
feasibility in clinical use of 3-dimensional spiral computed tomog-
raphy angiography for preoperative measurements in planning
endovascular abdominal aortic aneurysm repair (EVAR). In that
work the authors’ specific focus centered on volumetric measure-
ments.2 Their software model of computer-generated centerline
measurements also demonstrated high accuracy in measurement of
length, and was superior to sizing catheters or caliper measure-
ments. These findings are consistent with our currently reported
work in which we used the now commercially available MMS
software (Medical Metrx Solutions), and noted an associated
highly significant decrease in use of iliac extensions.
We agree that the issue of optimal length measurements in the
preoperative planning phase for EVARmay be more complex than
initially thought, and is likely to be affected by endograft-specific
design features that affect endograft flexibility and profile, as well as
patient-specific aneurysm anatomy such as degree of angulation
and tortuosity. As the technology for EVAR evolves, further study
of this subject may be required in efforts to optimize the types of
available computer-assisted software options, taking into account
all potentially important endograft-specific and anatomy-specific
features. The goal would continue to be decreased use of endograft
components and junctions, because these affect cost and expected
long-term durability of EVAR.
Omaida C. Velazquez, MD
Department of Surgery
Hospital of the University of Pennsylvania
Philadelphia, Pa
